New Frontiers: ARID3a in SLE

• Main Authors: Joshua Garton, M. David Barron, Michelle L. Ratliff, Carol F. Webb
• Format: Article
• Language: English
• Published: MDPI AG 2019-09-01
• Series: Cells
• Subjects: systemic lupus erythematosus; ARID3a; B lymphocytes; low-density neutrophils; plasmacytoid dendritic cells; interferon alpha
• Online Access: https://www.mdpi.com/2073-4409/8/10/1136

Systemic lupus erythematosus (SLE) is a devastating and heterogeneous autoimmune disease that affects multiple organs, and for which the underlying causes are unknown. The majority of SLE patients produce autoantibodies, have increased levels of type-I inflammatory cytokines, and can develop glomerulonephritis. Recent studies indicate an unexpected but strong association between increased disease activity in SLE patients and the expression of the DNA-binding protein ARID3a (A + T rich interaction domain protein 3a) in a number of peripheral blood cell types. ARID3a expression was first associated with autoantibody production in B cells; however, more recent findings also indicate associations with expression of the inflammatory cytokine interferon alpha in SLE plasmacytoid dendritic cells and low-density neutrophils. In addition, ARID3a is expressed in hematopoietic stem cells and some adult kidney progenitor cells. SLE cells expressing enhanced ARID3a levels show differential gene expression patterns compared with homologous healthy control cells, identifying new pathways potentially regulated by ARID3a. The associations of ARID3a expression with increased disease severity in SLE, suggest that it, or its downstream targets, may provide new therapeutic targets for SLE.